stephen
bent
md
sanjay
saint
md
mph
eric
vittinghoff
phd
deborah
gradi
md
mph
purpos
patient
acut
bronchiti
seek
medic
care
treat
antibiot
although
effect
intervent
uncertain
perform
metaanalysi
random
control
trial
estim
effect
antibiot
treatment
acut
bronchiti
subject
method
englishlanguag
studi
publish
januari
april
retriev
use
medlin
bibliographi
consult
expert
random
trial
enrol
otherwis
healthi
patient
diagnosi
acut
bronchiti
use
antibiot
treatment
group
placebo
control
group
provid
suffici
data
calcul
effect
size
includ
result
identifi
eight
random
control
trial
satisfi
inclus
criteria
studi
use
one
three
antibiot
erythromycin
doxycyclin
trimethoprim
sulfamethoxazol
use
antibiot
decreas
durat
cough
sputum
product
approxim
onehalf
day
summari
effect
size
ci
specif
symptom
nonsignific
trend
favor
use
antibiot
decreas
day
purul
sputum
ci
decreas
day
cough
ci
decreas
day
lost
work
ci
conclus
metaanalysi
suggest
small
benefit
use
antibiot
erythromycin
doxycyclin
trimethoprimsulfamethoxazol
treatment
acut
bronchiti
otherwis
healthi
patient
small
benefit
must
weigh
risk
side
effect
societ
cost
increas
antibiot
resist
believ
use
antibiot
justifi
patient
j
med
excerpta
medica
inc
cute
bronchiti
common
clinic
disord
character
acut
onset
cough
sputum
product
patient
histori
chronic
pulmonari
diseas
evid
pneumonia
sinus
definit
exclud
patient
acut
exacerb
underli
pulmonari
disord
previou
metaanalysi
found
antibiot
use
led
small
statist
signific
benefit
effect
antibiot
patient
acut
bronchiti
remain
uncertain
although
disord
tenth
common
diagnosi
seen
physician
unit
state
account
million
offic
visit
annual
etiolog
acut
bronchiti
unclear
studi
identifi
virus
adenoviru
rhinoviru
coronaviru
influenza
parainfluenza
respiratori
syncyti
viru
coxsackieviru
caus
major
patient
atyp
bacteria
includ
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
speci
report
caus
case
acut
bronchiti
typic
bacteria
streptococcu
pneumonia
haemophilu
influenza
branhamella
catarrhali
recov
sputum
patient
howev
import
posit
bacteri
cultur
sputum
known
mani
pathogen
part
oropharyng
flora
recent
evid
suggest
bronchiti
adult
may
caus
bordetella
pertussi
parapertussi
better
known
role
caus
whoop
cough
children
major
patient
diagnos
acut
bronchiti
unit
state
treat
antibiot
nationwid
survey
physician
gonzal
et
al
found
twothird
patient
without
underli
lung
diseas
diagnos
acut
bronchiti
treat
antibiot
anoth
survey
children
diagnosi
acut
bronchiti
given
prescript
antibiot
although
antibiot
often
use
treatment
acut
bronchiti
efficaci
uncertain
clinic
trial
examin
issu
yield
conflict
result
qualit
review
similarli
inconclus
widespread
antibiot
use
carri
substanti
cost
put
patient
risk
medic
side
effect
promot
antibiot
resist
clarifi
optim
treatment
disord
perform
metaanalysi
determin
whether
antibiot
benefici
patient
acut
bronchiti
use
explicit
inclus
exclus
criteria
accept
quantit
method
metaanalysi
provid
summari
estim
effect
may
clarifi
dispar
result
previou
trial
literatur
review
began
computer
medlin
search
use
subhead
bronchiti
drug
therapi
term
xs
acut
diseas
includ
englishlanguag
articl
publish
januari
april
refer
list
retriev
articl
scan
expert
consult
identifi
potenti
trial
identifi
medlin
search
inclus
criteria
consist
follow
random
trial
use
antibiot
treatment
group
placebo
control
group
subject
acut
bronchiti
histori
chronic
lung
diseas
pneumonia
exclud
chest
radiograph
clinic
exam
therapi
least
day
present
suffici
data
calcul
differ
efficaci
treatment
placebo
continu
variabl
studi
exclud
nonexperiment
design
compar
one
antibiot
anoth
without
placebo
arm
studi
two
author
independ
abstract
author
journal
titl
year
public
sampl
size
averag
age
subject
antibiot
regimen
use
major
outcom
measur
inclus
exclus
criteria
discrep
abstract
data
resolv
consensu
eight
elig
studi
use
common
outcom
measur
sever
outcom
avail
one
studi
chose
day
sputum
product
main
outcom
symptom
characterist
diseas
studi
includ
outcom
day
sputum
product
chose
outcom
studi
clinic
similar
sputum
product
score
cough
amount
score
transform
outcom
unit
standard
deviat
thu
give
compar
effect
size
differ
outcom
studyspecif
effect
size
differ
mean
outcom
antibiot
placebo
group
divid
pool
standard
deviat
outcom
measur
studi
summari
effect
size
across
studi
calcul
weight
averag
studyspecif
effect
size
weight
equal
invers
estim
varianc
signific
summari
effect
size
standard
estim
varianc
assess
compar
standard
normal
distribut
test
heterogen
calcul
compar
weight
averag
squar
differ
summari
studyspecif
effect
size
appropri
x
distribut
weight
use
calcul
use
standard
formula
assum
outcom
normal
distribut
sampl
size
approxim
equal
antibiot
placebo
group
also
calcul
summari
mean
differ
outcom
report
four
studi
summari
measur
weight
averag
differ
antibiot
placebo
group
mean
outcom
measur
studi
weight
given
invers
varianc
mean
differ
estim
use
pool
standard
deviat
studi
test
signific
observ
summari
mean
differ
heterogen
also
perform
examin
potenti
public
bia
use
correl
number
subject
effect
size
studi
small
studi
neg
result
less
like
publish
correl
number
subject
effect
size
would
larg
public
bia
signific
correl
number
subject
effect
size
search
identifi
report
includ
random
placebocontrol
trial
antibiot
treatment
acut
bronchiti
two
studi
exclud
insuffici
data
present
origin
articl
attempt
retriev
necessari
data
author
unsuccess
remain
eight
trial
use
one
three
antibiot
erythromycin
doxycyclin
trimethoprim
sulfamethoxazol
includ
metaanalysi
reason
exclus
list
tabl
characterist
random
control
trial
includ
two
exclud
insuffici
data
shown
tabl
overal
summari
effect
size
ci
indic
small
onefifth
standard
deviat
statist
signific
benefit
use
antibiot
figur
equival
approxim
one
half
day
less
cough
sputum
product
three
outcom
report
least
four
studi
tabl
although
result
favor
antibiot
none
statist
signific
day
purul
day
lost
work
effect
antibiot
treatment
day
lost
work
small
unlik
day
cough
sputum
product
approach
statist
signific
test
heterogen
signific
overal
summari
effect
size
p
day
sputum
product
p
suggest
result
homogen
combin
test
heterogen
signific
summari
mean
differ
day
lost
work
p
day
cough
result
mean
antibiot
group
minu
mean
placebo
group
main
outcom
measur
posit
result
indic
benefit
antibiot
neg
result
indic
benefit
placebo
effect
size
differ
mean
outcom
antibiot
placebo
group
divid
pool
standard
deviat
studi
provid
data
allow
calcul
confid
interv
continu
outcom
measur
therefor
could
includ
overal
summari
effect
size
cough
amount
score
patientreport
score
sever
scale
sputum
product
score
patientreport
score
sever
scale
sputum
product
score
patientreport
score
sever
scale
ci
confid
interv
effect
size
summari
overal
estim
effect
size
differ
mean
outcom
antibiot
placebo
group
divid
pool
standard
deviat
horizont
line
denot
confid
interv
dot
repres
point
estim
random
control
trial
evalu
efficaci
antibiot
acut
bronchiti
inconsist
result
eight
trial
includ
metaanalysi
four
show
benefit
use
antibiot
wherea
four
report
benefit
part
discrep
may
studi
use
differ
outcom
measur
uncertain
clinic
import
exampl
outcom
measur
one
trial
report
statist
signific
benefit
antibiot
includ
reduct
mean
temperatur
reduct
use
antihistamin
publish
trial
use
sever
outcom
measur
use
standard
effect
size
express
unit
standard
deviat
quantit
overal
effect
antibiot
therapi
chose
outcom
characterist
acut
bronchiti
day
sputum
product
six
studi
avail
use
similar
outcom
two
studi
cough
amount
score
sputum
product
score
found
small
statist
signific
benefit
use
antibiot
patient
acut
bronchiti
approxim
equal
onefifth
standard
deviat
unit
relat
observ
benefit
summari
effect
size
clinic
variabl
also
calcul
summari
mean
differ
outcom
report
least
four
trial
durat
sputum
product
durat
cough
day
lost
work
show
small
nonsignific
trend
favor
use
antibiot
metaanalysi
suggest
patient
acut
bronchiti
treat
antibiot
reduct
durat
cough
sputum
product
approxim
one
half
day
result
interpret
caution
metaanalys
assum
individu
trial
suffici
similar
provid
meaning
summari
studi
sever
import
differ
took
place
differ
geograph
locat
use
three
differ
antibiot
erythromycin
doxycyclin
trimethoprimsulfamethoxazol
conduct
period
howev
despit
differ
statist
test
heterogen
show
differ
studi
main
outcom
outcom
sputum
product
although
differ
antibiot
use
group
treat
least
day
spectrum
organ
cover
variou
antibiot
similar
identifi
random
control
trial
literatur
review
result
two
trial
could
includ
insuffici
data
report
trial
show
benefit
use
antibiot
thu
exclus
tend
bia
result
favor
antibiot
addit
summari
effect
size
may
overestim
public
bia
made
like
studi
show
benefit
publish
wherea
show
benefit
public
bia
small
studi
neg
find
unlik
publish
wherea
small
studi
posit
find
like
publish
lead
correl
studi
size
effect
size
found
correl
use
similar
methodolog
earlier
metaanalysi
examin
effect
antibiot
patient
acut
exacerb
chronic
obstruct
pulmonari
diseas
studi
report
summari
effect
size
ci
also
indic
small
statist
signific
benefit
use
antibiot
patient
treat
antibiot
modest
improv
peak
expiratori
flow
approxim
lmin
compar
treat
placebo
although
magnitud
benefit
antibiot
treatment
metaanalysi
similar
current
metaanalysi
benefit
may
import
patient
underli
lung
diseas
less
function
reserv
cost
widespread
antibiot
use
great
patient
societi
includ
prescript
cost
medic
side
effect
increas
antibiot
resist
sever
studi
shown
widespread
antibiot
use
lead
develop
resist
organ
antibiot
use
acut
bronchiti
constitut
substanti
portion
antibiot
use
unit
state
account
prescript
written
children
furthermor
side
effect
antibiot
use
acut
bronchiti
common
occur
patient
practic
routin
give
antibiot
acut
bronchiti
encourag
patient
expect
antibiot
subsequ
episod
add
cycl
medic
cost
side
effect
antibiot
resist
believ
clear
substanti
benefit
antibiot
justifi
cost
author
suggest
certain
subgroup
patient
acut
bronchiti
may
benefit
antibiot
studi
patient
randomli
assign
treatment
doxycyclin
placebo
verheij
et
al
report
doxycyclin
result
clinic
benefit
among
patient
older
year
felt
ill
studi
entri
howev
approxim
patient
studi
abnorm
lung
auscult
therefor
may
condit
pneumonia
would
show
larg
benefit
antibiot
treatment
other
suggest
treat
patient
test
posit
mycoplasma
pneumonia
chlamydia
pneumonia
although
evid
random
trial
support
practic
random
trial
use
erythromycin
treat
acut
bronchiti
king
et
al
found
differ
outcom
patient
test
posit
test
neg
mycoplasma
pneumonia
research
need
determin
subgroup
patient
like
substanti
benefit
treatment
antibiot
studi
includ
metaanalysi
examin
effect
one
three
differ
antibiot
erythromycin
doxycyclin
trimethoprimsulfamethoxazol
none
studi
use
one
newer
macrolid
floroquinolon
antibiot
awar
random
placebocontrol
trial
agent
adult
acut
bronchiti
futur
studi
determin
risk
benefit
associ
use
newer
antibiot
summari
found
statist
signific
benefit
use
antibiot
acut
bronchiti
treatment
reduc
durat
cough
sputum
product
approxim
one
half
day
decis
use
antibiot
treatment
adult
acut
bronchiti
must
weigh
cost
associ
widespread
use
agent
healthi
patient
acut
bronchiti
evid
chronic
pulmonari
diseas
believ
small
benefit
associ
antibiot
treatment
outweigh
risk
side
effect
increas
antibiot
resist
note
ad
proof
paper
submit
metaanalysi
similar
topic
publish
smucni
jj
becker
la
glazier
rh
mcisaac
w
antibiot
effect
treatment
acut
bronchiti
metaanalysi
j
fam
pract
